Clinical Trial ProgressSensorion has completed enrollment for its Phase 2a study of SENS-401, indicating progress in their clinical trial efforts.
Financial StabilitySensorion ended the year with EUR77m in cash after two successful funding rounds, ensuring financial stability.
Safety ProfileThe SENS-501 gene therapy product and surgical procedure were well-tolerated by all treated patients, with no serious adverse events reported.